However, with few exceptions, the stem cell and regenerative medicine industry has remained inadequately capitalized to carry out large - scale clinical trials independently, and major
pharmaceutical firms have tended to show more interest in the use of hiPSCs as a source of large,
pure populations of specific somatic cells for use in drug compound screening and toxicology tests,
than they have in therapeutic uses of stem cells and their derivatives.